I think the Neuland management may be able to add more color on the possible impact of this FDA approval. I anticipate a lot of questions on this topic from the investing community to the management team.
As the FDA approval was not a guarantee and if this approval leads to significant Rev uptick for Neuland over the next couple of years then I believe the stock may continue to re-rate. As long as they can continue to grow their Earnings substantially YoY the re-rating will continue to take place.
| Subscribe To Our Free Newsletter |
